The Night Shift: Sleep, Hormones, and the Menopause Transition

If you’ve started waking at 3 a.m. for no apparent reason, or lying awake while the rest of the household sleeps, you are not alone: sleep disruption is one of the most common and least-discussed symptoms of the menopause transition. In one large survey of midlife women, 60% reported insomnia or difficulty sleeping (Journal of Women's Health, 2013).

Yet many women spend years taking prescription sleep aids, such as Ambien, trying melatonin, and following well-meaning advice about screen time before anyone connects their sleeplessness to what is happening hormonally. Among women aged 45–64, 12.7% report using sleep medication four or more times per week. That rate is nearly double the rate of men in the same age group, and approaching the 13.2% rate seen among women over 65 (National Health Interview Survey, 2017–2018). It is a pattern that suggests the symptom (sleep disruption) is being treated while the underlying cause (hormonal changes) goes unaddressed.

Sleep changes during the menopause transition: what the research shows

Sleep problems are not simply a byproduct of aging. Large prospective studies, including the Study of Women's Health Across the Nation (SWAN) — one of the most comprehensive longitudinal studies of midlife women ever conducted — have documented that sleep disturbance follows the trajectory of hormonal change, not chronological age alone.

According to SWAN data, sleep disturbance peaks in the late perimenopause stage, when ovarian hormone production is most erratic and vasomotor symptoms (hot flashes and night sweats) are typically at their worst. After the final menstrual period, sleep complaints often stabilize for many women.

Among the specific changes women report:

• Difficulty falling asleep (sleep onset insomnia)
• Waking frequently during the night (sleep maintenance insomnia)
• Early-morning waking
• Feeling unrefreshed in the morning despite adequate hours in bed (non-restorative sleep)

In clinical terms, these map to sleep onset insomnia, sleep maintenance insomnia, and non-restorative sleep.

The role of vasomotor symptoms

The connection between hot flashes, night sweats, and sleep disruption is direct and well-established. Vasomotor symptoms affect approximately 80% of midlife women and can persist for a decade or longer (Avis et al., JAMA Internal Medicine, 2015). When a hot flash occurs at night, the resulting temperature spike and subsequent cooling, often accompanied by sweating and a racing heartbeat, fragments sleep at its deepest stages. Even brief nighttime awakenings, if they happen repeatedly, prevent the restorative slow-wave and REM sleep that the brain and body require.

Hot flashes that do not wake a woman consciously can still alter her brain activity during sleep. Research has documented subclinical sleep disturbance associated with vasomotor events, meaning the sleep architecture is disrupted even when the woman herself is unaware of it. This helps explain why many women feel exhausted even on nights they believe they slept through.

Hormonal changes beyond hot flashes

Hot flashes are not the only hormonal driver of disrupted sleep.

Progesterone, which declines significantly during perimenopause, has sedating properties and plays a role in regulating sleep architecture. Lower progesterone levels have been associated with increased nighttime waking and reduced time in slow-wave sleep.

Estrogen also affects the brain systems that regulate the sleep-wake cycle, including serotonin and norepinephrine pathways. As estrogen becomes more variable and eventually declines, mood changes, anxiety, and heightened wakefulness at night can further compromise sleep quality, creating a feedback loop in which poor sleep worsens mood and anxiety, which in turn worsens sleep.

Sleep apnea and the menopause transition

One underrecognized aspect of midlife sleep disruption is the increased risk of obstructive sleep apnea (OSA) after menopause. Before menopause, women are significantly less likely than men to develop OSA; after menopause, that gap narrows substantially.

Research has found that the severity of sleep-disordered breathing (including OSA) increases as women move through the menopause transition, independently of changes in body weight (Mirer et al., Menopause, 2017). This suggests a hormonal mechanism rather than weight gain alone.

OSA produces fragmented sleep, nighttime oxygen desaturation, and daytime fatigue that can be difficult to distinguish from menopausal symptoms. Women with persistent, unexplained fatigue or sleep problems that do not respond to usual interventions should discuss OSA screening with their clinician.

Why sleep disruption is not just an inconvenience

Poor sleep is often framed as an annoying but tolerable symptom. However, chronic sleep disruption during the menopause transition carries downstream health consequences that extend well beyond daytime fatigue.

Cardiometabolic risk. Sleep disturbance in midlife women has been independently associated with arterial stiffness, increased risk of the metabolic syndrome, and markers of subclinical cardiovascular disease including coronary artery calcification (SWAN Sleep Study). Multiple analyses from the SWAN cohort have found that women with sleep problems show early signs of arterial changes linked to heart disease. Poor sleep is now understood to be an independent risk factor for cardiovascular disease, not merely a companion symptom.

Cognitive function. Sleep is when the brain consolidates memory, clears metabolic byproducts, and restores cognitive function. Chronic sleep disruption at midlife has been linked to impaired memory and concentration. There is also reason to believe that chronic sleep disruption during perimenopause may play a role in longer-term cognitive aging and dementia risk, given the role sleep plays in clearing amyloid from the brain. The widespread interest in this connection is reflected in the success of neuroscientist Dr. Lisa Mosconi’s 2024 book The Menopause Brain, an instant New York Times, USA Today, and Sunday Times bestseller, which examines how the hormonal changes of menopause affect brain health and cognitive aging.

Mental health. Bidirectional relationships exist between sleep and mood. Poor sleep worsens anxiety and depression, and depression and anxiety worsen sleep. Women in perimenopause have a two- to five-fold higher risk of a major depressive episode compared to the late premenopausal years (Bromberger & Epperson, 2018). For many, addressing the underlying sleep disruption is an important component of managing mood.

Treatment options

The good news is that sleep disruption during the menopause transition is treatable.

Hormone therapy

For women whose sleep disruption is at least partially driven by vasomotor symptoms, hormone replacement therapy (HRT) is the most effective treatment currently available. By reducing hot flash frequency and severity, HRT removes the primary physiological disruptor of nighttime sleep.

Multiple randomized controlled trials have documented improved sleep quality in women receiving HRT compared to placebo. In the WISDOM trial — a large randomized controlled study — women on HRT reported improved sleep, reduced hot flashes and night sweats, and improved overall quality of life. The researchers specifically emphasized sleep improvement, noting that inadequate sleep is associated with increased risk of obesity, diabetes, hypertension, and cardiovascular disease.

Micronized progesterone (bioidentical progesterone) may offer additional sleep benefits beyond those of estrogen alone. Its sedating properties — derived from its action on GABA receptors in the brain — may help women fall asleep more easily and maintain deeper sleep stages. This is relevant both for women with a uterus (who require progesterone alongside estrogen) and as an area of growing clinical interest.

The 2022 NAMS Hormone Therapy Position Statement affirms HRT as appropriate and effective for women with bothersome menopause symptoms, including sleep disruption, when initiated within ten years of the final menstrual period or before age 60. For women in this window, the benefit-risk profile is favorable for most.

Cognitive behavioral therapy for insomnia (CBT-I)

CBT-I is the leading evidence-based, non-pharmacological treatment for chronic insomnia. It addresses the behavioral and thought patterns that perpetuate poor sleep: including sleep restriction, stimulus control, and cognitive restructuring of anxiety about sleep itself.

In studies of midlife women, CBT-I has been shown to reduce the bother and interference associated with vasomotor symptoms and improve sleep outcomes. Importantly, it does not address the hormonal drivers of disrupted sleep, but, for women who also have learned insomnia behaviors layered on top of hormonal disruption, combining CBT-I with HRT may produce better outcomes than either treatment alone.

CBT-I is available through trained therapists and increasingly through digital programs. For women who cannot or prefer not to use hormone replacement therapy, it is the most evidence-supported non-hormonal option for sleep.

Non-hormonal prescription options

For women who are not candidates for hormone replacement therapy, several prescription non-hormonal options can reduce vasomotor symptoms — and by extension, improve sleep. These include certain antidepressants (SSRIs and SNRIs) and fezolinetant, an FDA-approved neurokinin B antagonist specifically developed for moderate-to-severe vasomotor symptoms.

It is worth noting that these medications reduce vasomotor symptom frequency but do not address the underlying hormonal changes driving sleep disruption more broadly. Their effect sizes are generally smaller than those of HRT, and they carry their own side effect profiles. Gabapentin has also been used for sleep and vasomotor symptoms, though the benefit-risk balance warrants careful clinical discussion.

Sleep hygiene: helpful, but not sufficient

Sleep hygiene recommendations — consistent bedtimes, dark and cool rooms, limiting alcohol and caffeine, reducing screen time before bed — are widely promoted and sensible. But for women whose sleep is being disrupted by hot flashes, progesterone decline, and hormonal dysregulation, behavioral adjustments alone will generally not resolve the problem.

Cooling interventions (breathable bedding, a fan, or a cooling mattress pad) can reduce discomfort during nighttime hot flashes and may modestly reduce vasomotor-driven waking. These are worth trying as adjuncts but should not be positioned as primary treatment for significant sleep disruption.

A note on alcohol and sleep during menopause

Many women find that alcohol disrupts sleep more than it used to. This reflects a real pharmacological change: alcohol suppresses REM sleep and increases nighttime waking, particularly in the second half of the night. Combined with the hormonal factors already at play during perimenopause and menopause, alcohol can meaningfully worsen sleep quality even in amounts that felt manageable in earlier years. For women already struggling with sleep, reducing or eliminating alcohol often produces noticeable improvement.

Talking to your clinician

Sleep disruption during the menopause transition is frequently underreported and under-treated. Because symptoms like insomnia, fatigue, and mood changes can have many causes, they are sometimes addressed one at a time — with referrals to specialists and/or prescriptions for sleep medications the care provider frequently prescribes and is familiar with — before addressing hormonal changes.

If you are experiencing significant sleep disruption alongside other symptoms that may be related to perimenopause or menopause, it is worth raising all of these together. A clinician who understands the menopause transition can help evaluate whether hormonal factors are contributing and what treatment approach is most appropriate for you.

You do not have to accept disrupted sleep as an inevitable feature of midlife. Effective, evidence-based options exist — and treating the underlying cause is usually more effective than treating each symptom in isolation.

Key takeaways

Sleep disruption peaks in late perimenopause. This is not simply aging — it follows hormonal change, and vasomotor symptoms are a primary driver.

Poor sleep has real health consequences. Associations with cardiovascular risk, cognitive function, and mental health make this a clinical issue, not just a comfort one.

Hormone therapy is the most effective treatment. For women with vasomotor-driven sleep disruption, HRT addresses the underlying cause rather than the symptom alone.

CBT-I is the best non-hormonal option. It can be used alone or in combination with HRT.

Alcohol worsens sleep during the menopause transition. More so than in earlier life, for pharmacological reasons.

Ask about hormones. If your sleep disruption has coincided with other midlife changes, work with your clinician on a holistic and integrative treatment plan.

The most common questions we hear about sleep disruption during perimenopause and menopause

Is it normal to have trouble sleeping during perimenopause?

Yes. Sleep disruption is one of the most common symptoms of the menopause transition, reported by more than half of midlife women. It is not simply a sign of aging — it follows the pattern of hormonal change, particularly the rise and fall of estrogen and the decline of progesterone, and tends to peak in the late perimenopause stage.

Why do I keep waking up at night during menopause?

The most common cause is vasomotor symptoms (hot flashes and night sweats). When a hot flash occurs during sleep, the resulting temperature spike and the body’s effort to cool down fragments sleep, sometimes waking you and sometimes disrupting your sleep effectiveness without waking you at all. Declining progesterone levels also reduce the sedating effects that hormone normally provides, making it harder to stay in deep sleep.

How long does sleep disruption last during the menopause transition?

It varies. For many women, sleep problems improve after the final menstrual period as hormonal fluctuation stabilizes. For others, particularly those with persistent vasomotor symptoms, disrupted sleep can continue for several years into postmenopause. Vasomotor symptoms themselves can last a decade or longer in some women, so sleep disruption that goes untreated can be a long-term issue.

Will hormone replacement therapy (HRT) help me sleep better?

For women whose sleep disruption is at least partially driven by vasomotor symptoms, HRT is the most effective treatment available. By reducing hot flash frequency and severity, it removes the primary cause of nighttime waking. In women with vasomotor symptoms, multiple randomized controlled trials have documented improved sleep quality on HRT compared to placebo. Micronized progesterone, used in women with a uterus, may offer additional sleep benefits due to its mild sedating properties.

Can I use melatonin for menopause-related sleep problems?

Melatonin helps regulate the timing of sleep — when you fall asleep — but it does not address the underlying hormonal drivers of sleep disruption during the menopause transition. If your sleep problems are caused by hormonal changes that are occurring as you approach and pass menopause, melatonin is unlikely to provide meaningful relief on its own. It may be useful as an adjunct but should not substitute for evaluation of the hormonal causes.

Is it safe to take prescription sleep medications during menopause?

Prescription sleep medications can provide short-term relief, but they do not address the hormonal causes of sleep disruption during the menopause transition. Women aged 45–64 are prescribed sleep medications at some of the highest rates of any demographic — a pattern that often reflects treating the symptom rather than the underlying cause. If you have been prescribed sleep medication, it is worth discussing with your clinician whether hormonal factors may be contributing to your sleep problems.

Does CBT-I work for sleep problems during menopause?

Cognitive behavioral therapy for insomnia (CBT-I) is a structured, evidence-based program that targets the behaviors and thought patterns that perpetuate poor sleep. It is the leading non-pharmacological treatment for chronic insomnia and has been shown to reduce sleep disruption in midlife women. It works best when insomnia has a learned or behavioral component. For women whose sleep disruption is primarily driven by vasomotor symptoms, CBT-I alone may have limited benefit — but combining it with HRT can produce better outcomes than either approach alone.

Does poor sleep during perimenopause affect my long-term health?

Yes, and it is worth taking seriously. Chronic sleep disruption in midlife has been associated with increased cardiovascular risk, early signs of arterial changes linked to heart disease, impaired memory and concentration, and higher rates of anxiety and depression. There is also reason to believe that persistent sleep disruption may contribute to longer-term dementia risk, given the role sleep plays in clearing metabolic waste from the brain. Treating sleep disruption is not just about comfort — it is a meaningful health intervention.

Should I see a specialist about my sleep problems?

For most women, a good first step is to work with a menopause-informed clinician. If your sleep disruption has coincided with other midlife changes such as shifts in your menstrual cycle, mood, or hot flashes, hormonal factors are likely contributing, and a clinician who understands the menopause transition can evaluate whether hormone replacement therapy or other hormonal approaches are appropriate. Addressing the hormonal root cause often resolves sleep disruption without the need for specialist referral. That said, a sleep specialist may be warranted if your sleep problems persist despite hormonal treatment, if sleep apnea is suspected, or if there is reason to believe a separate sleep disorder is at play alongside the hormonal changes.

Bibliography

1. El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227.

2. Kravitz HM, Kazlauskaite R, Joffe H. Sleep, health, and metabolism in midlife women and menopause: food for thought. Obstet Gynecol Clin North Am. 2018;45(4):679–694.

3. Mirer AG, Young T, Palta M, et al. Sleep-disordered breathing and the menopausal transition among participants in the Sleep in Midlife Women Study. Menopause. 2017;24(2):157–162.

4. Kravitz HM, Janssen I, Bromberger JT, et al. Sleep trajectories before and after the final menstrual period in the Study of Women's Health Across the Nation (SWAN). Curr Sleep Med Rep. 2017;3(4):235–250.

5. Whiteley J, DiBonaventura M, Wagner JS, et al. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health (Larchmt). 2013;22(11):983–990.

6. Hall MH, Okun ML, Sowers M, et al. Sleep is associated with the metabolic syndrome in a multi-ethnic cohort of midlife women: the SWAN Sleep Study. Sleep. 2012;35(6):783–790.

7. Matthews KA, Everson-Rose SA, Kravitz HM, et al. Do reports of sleep disturbance relate to coronary and aortic calcification in healthy middle-aged women? Study of Women's Health Across the Nation. Sleep Med. 2013;14(3):282–287.

8. Zhou Y, Yang R, Li C, Tao M. Sleep disorder, an independent risk associated with arterial stiffness in menopause. Sci Rep. 2017;7:1904.

9. Thurston RC, Chang Y, von Känel R, et al. Sleep characteristics and carotid atherosclerosis among midlife women. Sleep. 2017;40(2):zsw052.

10. Bromberger JT, Epperson CN. Depression during and after the perimenopause: impact of hormones, genetics, and environmental determinants of disease. Obstet Gynecol Clin North Am. 2018;45(4):663–678.

11. Davis SR, et al. Paul Dudley White Lecture 2025: Do Sex Steroids Matter? (Transcript). Presented at Harvard Medical School / Massachusetts General Hospital, 2025.

12. The Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of The Menopause Society. Menopause. 2022;29(7):767–794.

13. The Menopause Society (NAMS). The 2023 Nonhormone Therapy Position Statement of The Menopause Society. Menopause. 2023;30(6):573–590.

14. Welton AJ, Vickers MR, Kim J, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ. 2008;337:a1190. [WISDOM trial]

15. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539.

16. Bluming AV, Tavris C. Estrogen Matters. New York: Little, Brown Spark; 2018.

17. Santoro N, Lasley B, Azziz R, et al. Reproductive hormone changes and sleep in midlife women. Sleep Med Clin. 2010;5(1):121–133.

18. El Khoudary SR, Thurston RC. Cardiovascular implications of the menopause transition: endogenous sex hormones and vasomotor symptoms. Obstet Gynecol Clin North Am. 2018;45(4):641–661.

19. Centers for Disease Control and Prevention (CDC). QuickStats: Percentage of Adults Aged ≥18 Years Who Took Medication To Help Fall or Stay Asleep Four or More Times in the Past Week, by Sex and Age Group. National Health Interview Survey, United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2019;68(49):1150. DOI: 10.15585/mmwr.mm6849a5. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6919287/